| Size | Price | Stock | Qty |
|---|---|---|---|
| 50mg |
|
||
| 500mg | |||
| 1g | |||
| Other Sizes |
| Targets |
The compound does not have a biological target; it is a chemical labeling reagent. The maleimide group is thiol-reactive, forming stable thioether bonds with free cysteine residues on proteins. The THP-thioester protecting group prevents premature reaction. It is used as a biochemical assay reagent for the development of PROTAC molecules and for site-specific bioconjugation in drug delivery systems.
|
|---|---|
| ln Vitro |
In vitro, THP-Mal (1-100 uM) is used for site-specific labeling of thiol-containing biomolecules. The compound is incubated with a protein of interest at neutral pH (7.0-8.0); the maleimide is inert due to the THP protection. Upon adjusting the pH to 2.0-3.0 for 10-30 min, the protecting group is removed, activating the maleimide for conjugation to a second thiol-containing molecule. Labeling efficiency is assessed by SDS-PAGE, mass spectrometry, or fluorescence if a dye is attached.
|
| ln Vivo |
Not applicable; not administered in vivo.
|
| Enzyme Assay |
Not applicable. For quality control, purity is >95% by HPLC. The compound is characterized by ¹H NMR and MS. Solubility is high in DMSO and DMF. For labeling reactions, protein (1-10 mg/mL) is mixed with THP-Mal (2-20× molar excess) in PBS (pH 7.0-7.5) for 1-2 h. The pH is then lowered to 2.0-3.0 with 0.1 M HCl or acetate buffer for 10-30 min to activate the maleimide. A second thiol-containing protein or fluorophore is added, and the mixture is incubated at pH 7.0 for 1-2 h. Cross-linked products are analyzed by SDS-PAGE.
|
| Cell Assay |
For cell-based labeling, cells are incubated with THP-Mal (10-200 uM) for 1-4 h, then washed and treated with pH 2.0-3.0 buffer to trigger activation. Labeling of surface thiols (reduced cysteines) is assessed by fluorescence microscopy or flow cytometry if THP-Mal is conjugated to a fluorophore. For cytotoxicity, cells are treated with 1-100 uM for 24-48 h; IC₅0 > 50 uM.
|
| Animal Protocol |
Not applicable.
|
| ADME/Pharmacokinetics |
High MW PEG-like molecule. Soluble in DMSO. Not for systemic administration.
|
| Toxicity/Toxicokinetics |
May cause skin and eye irritation. Use PPE. Not a drug.
|
| Additional Infomation |
THP-Mal is a research-grade maleimide labeling reagent for site-specific bioconjugation. It is not an FDA-approved drug. For research use only.
|
| Molecular Formula |
C65H75N9O13
|
|---|---|
| Molecular Weight |
1190.34
|
| Exact Mass |
1189.548
|
| CAS # |
1314929-99-1
|
| PubChem CID |
138376282
|
| Appearance |
Typically exists as solids at room temperature
|
| Hydrogen Bond Donor Count |
5
|
| Hydrogen Bond Acceptor Count |
16
|
| Rotatable Bond Count |
31
|
| Heavy Atom Count |
87
|
| Complexity |
2570
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
O=C(CCNC(CCN1C(C=CC1=O)=O)=O)NC(CCC(NCC1=C(C(C=C(C)N1C)=O)OCC1C=CC=CC=1)=O)(CCC(NCC1=C(C(C=C(C)N1C)=O)OCC1C=CC=CC=1)=O)CCC(NCC1=C(C(C=C(C)N1C)=O)OCC1C=CC=CC=1)=O
|
| InChi Key |
METBHPNAPCROQL-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C65H75N9O13/c1-43-34-52(75)62(85-40-46-16-10-7-11-17-46)49(71(43)4)37-67-55(78)24-29-65(70-59(82)27-32-66-58(81)28-33-74-60(83)22-23-61(74)84,30-25-56(79)68-38-50-63(53(76)35-44(2)72(50)5)86-41-47-18-12-8-13-19-47)31-26-57(80)69-39-51-64(54(77)36-45(3)73(51)6)87-42-48-20-14-9-15-21-48/h7-23,34-36H,24-33,37-42H2,1-6H3,(H,66,81)(H,67,78)(H,68,79)(H,69,80)(H,70,82)
|
| Chemical Name |
N,N'-bis[(1,6-dimethyl-4-oxo-3-phenylmethoxy-2-pyridinyl)methyl]-4-[3-[(1,6-dimethyl-4-oxo-3-phenylmethoxy-2-pyridinyl)methylamino]-3-oxopropyl]-4-[3-[3-(2,5-dioxopyrrol-1-yl)propanoylamino]propanoylamino]heptanediamide
|
| Synonyms |
THP-Mal
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 0.8401 mL | 4.2005 mL | 8.4010 mL | |
| 5 mM | 0.1680 mL | 0.8401 mL | 1.6802 mL | |
| 10 mM | 0.0840 mL | 0.4200 mL | 0.8401 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
